During the fall regenerative medicine and pharmaceutical conference seasons, Boston biotechnology company Asymmetrex, LLC will announce its new contract service for counting adult tissue stem cells. In three different conference venues, the company will relate how its new AlphaSTEM Test service can provide, for the first time, stem cell dose data for stem cell treatments
Asymmetrex Director Edits Newly Released Book on Human Stem Cell Toxicology Today, August 11, 2016, Royal Society of Chemistry Publishing in the UK released a new volume that is a first scholarly treatment of the emerging research and medical discipline of human stem cell toxicology. The 175 years old organization, which is the oldest
Asymmetrex continues to court gene-editing companies; Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics to name a few. Asymmetrex wants to dance with these companies into the new era of gene-editing therapeutics. Asymmetrex started pursuing them late in 2015. Today, the company announced that it would begin courting the companies’ scientists at conferences focused on gene-editing research and progress
Does Counting Adult Tissue Stem Cells Have a Human Impact? Asymmetrex’s 3-month campaign to increase awareness of the adult tissue stem cell counting problem has focused on how its AlphaSTEM technology solution could impact research and clinical practice. Now, the final post in the series answers the question, “Does counting adult tissue stem cells have
Webinar: A first technology for counting adult tissue stem cells for applications in regenerative medicine and drug development Since the first discovery of adult tissue stem cells, it has been impossible to count them. This conundrum persists because neither morphological nor molecular properties have been defined that distinguish tissue stem cells from more abundant committed
On March 22, Boston stem cell medicine technology start-up Asymmetrex will present a free, public, online webinar with the goal of discussing how it developed a stem cell technology that has been needed since the beginnings of stem cell biology. Hosted by RegMedNet, a London-based social media network for regenerative medicine professionals, the webinar will
In a RegMedNet post today (March 9, 2016), Asymmetrex explains that, although much attention is given to molecular genetics advances in the efficiency and integrity of new technologies for gene therapy, failure to count tissue stem cells is likely to limit future treatment success. Sufficient genetic engineering and transplantation of targeted tissue stem cells, like
In Upcoming Webinar and Conferences, Asymmetrex Will Intensify Education on Counting Adult Tissue Stem Cells For Regenerative Medicine and Drug Development As 2015 drew to a close, stem cell medicine biotechnology start-up company Asymmetrex began an effort to educate the pharmaceutical and regenerative medicine industries on the value of counting adult tissue stem cells. The
Cliches abound to describe the “unique” properties of adult tissue stem cells. The lay publications of the National Institutes of Health are full of them. “Self-renew.” “Differentiate.” “Multipotent.” The problem with lazy cliches is that they often understate and distort the calming and terrifying beauty of life. The life of adult stem cells is no
With its recently described improved technologies for specifically identifying adult tissue stem cells or detecting their function by a computer simulation technology, biotech start-up Asymmetrex is anticipating a need for rules to move the field of stem cell biology from a past of common errors and misconceptions to a future of exact quantification. Asymmetrex’s 5